ID   ZR-75-9a1
AC   CVCL_5613
DR   cancercelllines; CVCL_5613
DR   Wikidata; Q54996121
RX   PubMed=2713239;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_41774; Tamoxifen.
CC   Sequence variation: Mutation; HGNC; HGNC:5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0588 ! ZR-75-1
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 19
//
RX   PubMed=2713239; DOI=10.1038/bjc.1989.107; PMCID=PMC2247166;
RA   van den Berg, Hendrik W.
RA   Lynch, Maria
RA   Martin, Jose
RA   Nelson, John
RA   Dickson, Glenn R.
RA   Crockard, Alistair D.
RT   "Characterisation of a tamoxifen-resistant variant of the ZR-75-1
RT   human breast cancer cell line (ZR-75-9a1) and ability of the resistant
RT   phenotype.";
RL   Br. J. Cancer 59:522-526(1989).
//